Advertisement
U.S. markets closed
  • S&P 500

    5,137.08
    +40.81 (+0.80%)
     
  • Dow 30

    39,087.38
    +90.99 (+0.23%)
     
  • Nasdaq

    16,274.94
    +183.02 (+1.14%)
     
  • Russell 2000

    2,076.39
    +21.55 (+1.05%)
     
  • Crude Oil

    79.81
    +1.55 (+1.98%)
     
  • Gold

    2,091.60
    +36.90 (+1.80%)
     
  • Silver

    23.34
    +0.46 (+2.01%)
     
  • EUR/USD

    1.0839
    +0.0032 (+0.29%)
     
  • 10-Yr Bond

    4.1800
    -0.0720 (-1.69%)
     
  • GBP/USD

    1.2655
    +0.0029 (+0.23%)
     
  • USD/JPY

    150.0640
    +0.0800 (+0.05%)
     
  • Bitcoin USD

    62,111.93
    +19.48 (+0.03%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,682.50
    +52.48 (+0.69%)
     
  • Nikkei 225

    39,910.82
    +744.63 (+1.90%)
     

Human Longevity plans to go public in $1 bln blank-check deal

June 20 (Reuters) - Genome sequencing company Human Longevity Inc plans to go public through a merger with Freedom Acquisition I Corp that values the combined company at about $1 billion, the two companies said on Monday.

The announcement followed the signing of a non-binding letter of intent, although the companies said that there is no assurance of a definitive agreement or completion of a deal.

Freedom Acquisition I Corp is a special purpose acquisition company led by former Credit Suisse chief executive Tidjane Thiam, and was listed early last year.

A blank-check firm, or a special purpose acquisition company (SPAC), is a listed shell entity that uses the money raised in its IPO to merge with a private company, taking it public in the process. (Reporting by Leroy Leo in Bengaluru; editing by Richard Pullin)

Advertisement